公司資料
Puma Biotechnology Inc 股價、新聞與催化劑
- 股票代碼:
- PBYI
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
9.84 USD (-0.91%)
收盤價
最後更新: 2026年10月1日
355M USD
市值
股價為何變動
截至 2026年10月1日，PBYI 下跌 0.91%，收於 $9.84。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Commercial Oncology Company
Puma Biotechnology develops and commercializes therapies for breast cancer and other solid tumors. Its business combines the established NERLYNX franchise with clinical development of the Aurora kinase A inhibitor alisertib.
NERLYNX in HER2-Positive Breast Cancer
NERLYNX, or neratinib, is an oral irreversible pan-HER kinase inhibitor. It is approved as extended adjuvant treatment after trastuzumab-based therapy in early-stage HER2-positive breast cancer and with capecitabine in previously treated advanced or metastatic HER2-positive disease.
U.S. Commercial and International Royalty Model
Puma directly markets NERLYNX in the United States and supports access through its Patient Lynx program. International partners commercialize neratinib in other territories, providing Puma with royalty and licensing revenue.
Alisertib Development Program
Alisertib is an oral, selective inhibitor of Aurora kinase A, a protein involved in mitotic progression. Puma licensed global development and commercialization rights and is initially focusing the program on small cell lung cancer and hormone receptor-positive, HER2-negative metastatic breast cancer.
ALISCA Clinical Portfolio
ALISCA-Lung1 evaluates alisertib monotherapy in extensive-stage small cell lung cancer, while ALISCA-Lung2 evaluates alisertib with paclitaxel. ALISCA-Breast1 combines alisertib with endocrine therapy in chemotherapy-naive metastatic breast cancer.
未來催化劑
- Initiation of enrollment in the ALISCA-Lung2 Phase 1/2 trial in the third quarter of 2026.
- Enrollment expansion in ALISCA-Lung1 and ALISCA-Breast1 in the second half of 2026.
- Updated Phase 2 data from ALISCA-Breast1 in the fourth quarter of 2026.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。